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ExtEndEd rEport
Predicting and managing primary and secondary 
non-response to rituximab using B-cell biomarkers in 
systemic lupus erythematosus
Md Yuzaiful Md Yusof,1,2 daniel Shaw,1 Yasser M El-Sherbiny,1,2,3 Emma dunn,4 
Andy C rawstron,5 paul Emery,1,2 Edward M Vital1,2
AbstrACt
Objective to assess factors associated with primary 
and secondary non-response to rituximab in systemic 
lupus erythematosus (SLE) and evaluate management of 
secondary non-depletion non-response (2ndnr).
Methods 125 patients with SLE treated with rituximab 
over 12 years were studied prospectively. A major clinical 
response was defined as improvement of all active British 
Isles Lupus Assessment Group (BILAG)-2004 domains 
to grade C/better and no A/B flare. partial responders 
were defined by one persistent BILAG B. B-cell subsets 
were measured using highly sensitive flow cytometry. 
patients with 2ndnr, defined by infusion reaction and 
defective depletion, were treated with ocrelizumab or 
ofatumumab.
results 117 patients had evaluable data. In cycle 
1 (C1), 96/117 (82%) achieved BILAG response 
(major=50%, partial=32%). In multivariable analysis, 
younger age (or 0.97, 95% CI 0.94 to 1.00) and 
B-cell depletion at 6 weeks (or 3.22, 95% CI 1.24 to 
8.33) increased the odds of major response. Complete 
depletion was predicted by normal complement and 
lower pre-rituximab plasmablasts and was not associated 
with increased serious infection post-rituximab. Seventy-
seven (with data on 72) C1 responders were retreated 
on clinical relapse. of these, 61/72 (85%) responded 
in cycle 2 (C2). of the 11 C2 non-responders, nine met 
2ndnr criteria (incidence=12%) and tested positive 
for anti-rituximab antibodies. Lack of concomitant 
immunosuppressant and higher pre-rituximab 
plasmablasts predicted 2ndnr. Five were switched 
to ocrelizumab/ofatumumab, and all depleted and 
responded.
Conclusion treatment with anti-Cd20 agents can be 
guided by B-cell monitoring and should aim to achieve 
complete depletion. 2ndnr is associated with anti-
rituximab antibodies, and switching to humanised agents 
restores depletion and response. In SLE, alternative anti-
Cd20 antibodies may be more consistently effective.
IntrOduCtIOn
Rituximab, a chimeric anti-CD20 monoclonal 
antibody (mAb) remains an important treatment 
option for moderate to severe systemic lupus 
erythematosus (SLE). A high degree of efficacy 
of rituximab across a range of lupus manifesta-
tions has been reported in open-label studies from 
single-centre series,1–3 multicentre registries4–6 and 
a systematic review of off-label use.7 Despite the 
success of these series, two phase III randomised 
placebo-controlled trials in non-renal lupus8 and 
renal lupus9 failed to meet their primary end-points. 
The discrepancy between the randomised trials and 
real-world evidence has been attributed to aspects 
of trial design including choice of end-points, the 
use of an active comparator, inclusion criteria and 
low statistical power.10
Nevertheless, there are also mechanistic reasons 
for the failure of rituximab in clinical trials in SLE. 
B-cell killing by rituximab appeared less efficient 
in SLE than rheumatoid arthritis (RA)11 due to 
internalisation through interaction with FcγRIIb 
resulting in reduced effector activity12 and patho-
genic lupus autoantibodies that were produced by 
long-lived plasma cells.13 14 Using highly sensitive 
flow cytometry (HSFC), a protocol that was opti-
mised for the detection of plasmablasts, we discov-
ered that the depth of B-cell depletion predicted 
response in RA15 and SLE.2 Similar studies as well as 
identifying other clinical predictors of response to 
rituximab in SLE are needed to optimise its use and 
to help design trials of alternative B-cell depleting 
strategies.
B-cell depletion therapy with rituximab is tran-
sient. Some patients with initial good response 
experience relapse after B-cell repopulation 
(although with a variable interval). In our published 
discovery cohort, we showed a bimodal pattern 
of relapse. Earlier relapse requiring rituximab 
retreatment was predicted by a plasmablast count 
of >0.0008×109/L at 6 months (the time of initial 
clinical response).2 Patients with lower plasmablasts 
at 6 months had sustained response without retreat-
ment. Validation of this as a biomarker is therefore 
needed to determine whether HSFC can be used in 
clinical practice to guide retreatment decisions.
Repeat treatment with rituximab is effective.1 
However, we observed cases of patients with SLE 
who had previously depleted and responded well 
to rituximab but subsequently developed (1) a 
severe infusion reaction >24 hours during the 
second infusion of a cycle, (2) failure to deplete 
CD20+ (naïve and memory) B-cells and (3) clinical 
non-response during repeat cycles. We called this 
phenomenon secondary non-depletion and non-re-
sponse (2NDNR), which was suggestive of immu-
nogenicity to rituximab and could be overcome by 
alternative anti-CD20 mAbs, particularly human-
ised. Therefore, the aims of the study were to assess 
factors predicting primary and secondary non-re-
sponse to rituximab in SLE including validation of 
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B-cell depletion and to evaluate management of 2NDNR using 
alternative anti-CD20 agents.
MethOds
Patients and design
A prospective observational study was conducted of all patients 
with moderate to severe SLE who were treated with rituximab 
in Leeds between January 2004 and July 2016. Inclusion criteria 
included (1) adults (>16 years old); (2) fulfilling the revised 1997 
American College of Rheumatology classification for SLE16 and 
(3) at least 6 months follow-up post-rituximab.
treatment protocol
All patients received a first cycle of therapy consisting of 100 mg 
of methylprednisolone and 1000 mg of rituximab given intra-
venously on days 1 and 14. Further cycles of the same regimen 
were repeated on clinical relapse (defined below).
Of those who met 2NDNR criteria, their treatment was 
switched from rituximab to humanised anti-CD20 mAbs either 
by using (1) 2×1000 mg ocrelizumab (compassionate use from 
Roche UK) or (2) 2×700 mg ofatumumab (individual funding 
request to NHS England).
Clinical data and outcomes
Disease activity was assessed using the British Isles Lupus Assess-
ment Group (BILAG-2004)17 at baseline and every 3 months 
thereafter. Clinical responses at 6 months were determined 
as following: (1) major clinical response=improvement of all 
domains rated A/B to grade C/better and no A/B flare between 
baseline and 6 months; (2) partial clinical response=maximum 
of 1 domain with a persistent grade B with improvement in all 
other domains and no A or B flare and (3) non-response=those 
not meeting the criteria for major or partial clinical response. 
Relapse was defined as a new grade A or recurrence of ≥1 grade 
B following either major/partial clinical response at 6 months. 
Global BILAG score was calculated as follows: grade A=12, 
grade B=8, grade C=1 and grades D and E=0.18
Laboratory assessments
Peripheral blood B-cell subsets (naïve, memory B-cells and 
plasmablasts) were measured using HSFC as previously 
described15 at baseline, 6 months and every 6 months without 
knowledge of clinical status other than time since rituximab. 
Complete B-cell depletion was defined as counts <0.0001×109/L 
and repopulation as ≥0.0001×109/L.
Anti-dsDNA antibody titres were measured by ELISA until 
July 2012 and Bioplex 2200 Immunoassay (after July 2012). 
Complement levels (C3 and C4) and total serum immunoglob-
ulin titres were measured by nephelometry.
Anti-rituximab antibodies were tested on a subset of patients 
with 2NDNR using the Promonitor® Anti-Rituximab ELISA 
according to the manufacturer’s instructions and compared 
these concentrations to those with continued response to ritux-
imab. A positive test (as determined by the manufacturer) was 
concentration >140 AU/mL.
safety
Serious infections were recorded irrespective of suspected asso-
ciation with SLE and/or therapy. These were infections that 
resulted in hospitalisation for >24 hours or required intravenous 
antibiotics. Details about other safety assessment can be found in 
online supplementary files.
statistical analysis
Descriptive statistics were summarised using mean with SD or 
median with IQR for continuous variables and proportion for 
categorical variables. Multiple imputation was used for missing 
data. Multivariable analyses were performed using logistic 
regression after checking for multicollinearity. The significance 
of the association between categorical variables was tested by 
Fisher’s exact test, while for continuous variables using Mann-
Whitney U test. Receiver operator curves (ROCs) were used 
to measure sensitivity and specificity of optimal thresholds for 
investigations predicting time-to-clinical relapse.
All statistical analysis was performed using Stata V.13.1 and 
Graph Pad Prism V.6.01 for Windows.
resuLts
Patient characteristics
Of 125 patients with SLE who were treated with rituximab at 
our unit, 117 patients with evaluable data at 6 months were 
studied. Baseline characteristics are described in table 1. One 
hundred and twelve (96%) had refractory and active disease as 
defined by BILAG ≥1A score and/or ≥2B scores. The remaining 
five had BILAG B in one domain only but was refractory to other 
conventional therapies as well as on maintenance with oral pred-
nisolone ≥10 mg daily. Total follow-up was 492 patient-years.
treatment characteristics
Three hundred and eighteen cycles of rituximab were admin-
istered. Median (range) duration of response in rituximab 
responders for cycles 1–4 (C1–4) were 52 (26–423), 52 
(26—299), 57 (27–184) and 50 (29–173) weeks, respectively.
Concomitant cyclophosphamide was used in five patients who 
presented with life-threatening flare.
Clinical and immunological response to first cycle rituximab
In C1, there was a good overall clinical response to rituximab. 
Fifty-eight (50%) patients had major clinical response, 38 (32%) 
partial clinical response and 21 (18%) were non-responders. The 
median global BILAG scores had reduced from 21 (IQR 14–27) 
pre-rituximab to 8 (IQR 1–10) at 6 months; p<0.001.
Responses in individual BILAG domains are shown in 
figure 1A. Although majority of domains improved, responses 
were more variable in the mucocutaneous and haematolog-
ical domains. Mucocutaneous responses to rituximab have 
been described in detail previously.19 These long-term data 
showed a more consistent major response in lupus erythema-
tosus non-specific lesions and oral ulcers, while non-response in 
chronic cutaneous lupus erythematosus (CCLE) (CCLE vs other 
lupus-specific lesions; p=0.022).
The median serum anti-dsDNA titre had reduced from 109 
(IQR 16–300) IU/mL pre-rituximab to 32 (IQR 7–116) IU/mL at 
6 months; p<0.001. Of 46 patients with low complement (C3 
and/or C4) levels pre-rituximab, levels had normalised in 25/46 
(54%) at 6 months.
Predictors of major clinical response to first cycle rituximab
Only B-cell depletion at 6 weeks increased the odds of BILAG 
response (major/partial) in multivariable analysis; adjusted 
imputed OR 13.93, 95% CI 3.11 to 62.37; p=0.001 (online 
supplementary table S2).
As there was a high degree of response to rituximab in this 
cohort, we analysed predictors for major clinical response sepa-
rately in order to identify patients who would respond best to 
therapy. In imputed univariable analysis, only younger age was 
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associated with major response to rituximab (OR 0.97, 95% CI 
0.95 to 0.99; p=0.031). While in imputed multivariable model, 
younger age (OR 0.97, 95% CI 0.94 to 1.00; p=0.045) and 
B-cell depletion at 6 weeks post-rituximab (OR 3.22, 95% CI 
1.24 to 8.33; p=0.016) increased the odds of major response to 
rituximab (table 2).
Validation of association between complete b-cell depletion 
and clinical response
The published discovery cohort included 37 patients with 
SLE.2 In this validation cohort, 67 subsequent and consecutive 
patients (with B-cell data available) were analysed. Similar to the 
discovery cohort, higher response rate was achieved in complete 
depletion compared with incomplete depletion groups (93% vs 
68%; p=0.011) in this validation cohort (figure 1B).
While there was no difference at baseline, patients with 
complete B-cell depletion had significantly lower anti-dsDNA 
antibody titres at 14 weeks (p=0.030) and 26 weeks (p=0.041) 
versus those with incomplete depletion. In the former, C3 
and C4 levels were not different at 14 weeks (p=0.064 and 
p=0.148, respectively) but were higher at 26 weeks (p=0.020 and 
p=0.022, respectively) compared with the latter group. There 
was no difference in anti-ENA antibodies between the two 
groups at 14 and 26 weeks; all p>0.10.
Predictors for complete b-cell depletion to first cycle 
rituximab
Data for B-cell subsets were available for 104 (89%) patients. 
In imputed univariable analysis, higher anti-dsDNA titre (OR 
1.00, 95% CI 0.99 to 1.00; p=0.038), normal complement 
levels (OR 0.41, 95% CI 0.18 to 0.91; p=0.028) and lower 
pre-rituximab plasmablasts (OR 0.88, 95% CI 0.80 to 0.98; 
p=0.015) were associated with complete B-cell depletion. While 
in imputed multivariable model, only normal complement levels 
(OR 0.29, 95% CI 0.09 to 0.90; p=0.032) and lower pre-ritux-
imab plasmablasts (OR 0.86, 95% CI 0.78 to 0.96; p=0.007) 
predicted complete B-cell depletion post-rituximab (online 
supplementary table S4).
b-cell depletion and associated serious infection
As most of the serious infection episodes occurred in C1 and 
C2 (n=23 in 15 patients), we analysed the association between 
complete B-cell depletion and serious infection. After two cycles, 
there were no difference in the serious infection rates between 
complete and incomplete depletion groups (8/98 (8.2%) and 
7/73 (9.6%), respectively; p=0.789).
Plasmablast repopulation as a biomarker of relapse
At 6 months, B-cells were detectable in 81% of the C1 responders. 
This time-point preceded all relapses. As the median of dura-
tion of response was 52 weeks, we divided the patients in this 
validation cohort (n=25 with B-cells data available) into two 
groups: (1) earlier relapse (≤12 months from first rituximab) 
and (2) later relapse (>12 months). A 12-month relapse time is 
clinically significant as it indicates that a 6-monthly retreatment 
may not be necessarily needed in these patients. Similar to the 
discovery cohort, the ROC indicated that a plasmablast count 
of >0.0008×109/L at 6 months yielded 73% (95% CI 45% to 
92%) sensitivity and 90% (95% CI 56% to 99%) specificity in 
predicting earlier relapse; area under the curve of 0.86 (online 
supplementary figure S1).
Of the patients with plasmablasts >0.0008×109/L at 6 
months, relapse rates within the next 26 and 52 weeks were 
90% and 100%, respectively. While of the patients with 
plasmablasts ≤0.0008×109/L at 6 months, relapse rates within 
table 1 Baseline characteristics of the 117 patients with SLE 
treated with rituximab
Age at first RTX infusion, median (IQR) years 39 (26–52)
No. female patient (%) 109 (93)
Ethnicity, N (%)
  Caucasian 80 (68)
  Afro-Caribbean 11 (10)
  South Asian 20 (17)
  Other 6 (5)
SLE disease duration at first RTX, median 
(IQR) years
6 (2–11)
Positive ANA at diagnosis, N (%) 117 (100)
Antibody status at first RTX infusion, N (%) 
Positive
108 (92)
  anti-dsDNA 56 (48)
  Anti-Ro 57 (49)
  Anti-La 18 (15)
  Anti-Smith 15 (13)
  Anti-Chromatin 19 (16)
  Anti-RNP 23 (20)
  Anti-Ribosomal P 6 (5)
  Anti-Cardiolipin/anti-B2-glycoprotein 14 (12)
Prior CYC therapy, N (%) 63 (54)
  Cumulative dose of CYC, mean ± SD gram    6.6 ± 4.2
Number of prior immunosuppressant failure 
(including CYC but excluding glucocorticoid), 
median (range)
3 (0–9)
Concomitant antimalarials, N (%) 88 (75)
Concomitant immunosuppressant, N (%)
  Azathioprine 19 (16)
  Methotrexate 16 (14)
  Mycophenolate Mofetil 39 (33)
Prednisolone dose at first RTX infusion, 
median (IQR) mg
10 (3–20)
ESR at first RTX infusion, median (IQR) mm/
hour
29 (15–57)
BILAG index score at baseline, N (%)
  ≥1 A score 96 (82)
  No A score but ≥2 B scores 16 (14)
BILAG domains at baseline, N (%) Grade A Grade B
  General 9 (8) 12 (10)
  Mucocutaneous 23 (20) 32 (27)
  Neurological 17 (15) 17 (15)
  Musculoskeletal 30 (26) 24 (20)
  Cardiorespiratory 6 (5) 13 (11)
  Gastrointestinal 6 (5) 0 (0)
  Ophthalmic 0 (0) 0 (0)
  Renal 34 (29) 0 (0)
  Haematology 11 (9) 12 (10)
Global BILAG score, median (IQR) 21 (14–27)
SLEDAI-2K score, median (IQR) 10 (6–14)
SLICC Damage Index, median (IQR) 0 (0–1)
ANA, antinuclear antibody; BILAG, British Isles Lupus Assessment Group; CYC, 
cyclophosphamide; dsDNA, double-stranded DNA; ESR, erythrocyte sedimentation 
rate; RNP, ribonucleic protein; RTX, rituximab; SLEDAI-2K, Systemic Lupus 
Erythematosus Disease Activity Index 2000; SLICC, Systemic Lupus International 
Collaborating Clinics (SLICC).
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the next 26 and 52 weeks were 33% and 73%, respectively 
(figure 2A).
There were no differences in anti-dsDNA titres, total 
BILAG score and memory B-cells at 6 months between the 
earlier versus later relapse groups, p=0.475, p=0.985 and 
p=0.414, respectively.
retreatment of first cycle non-responders
In RA, we showed that retreatment of initial non-responders 
with incomplete B-cell depletion led to improved response 
rate in C2.20 Of the 21 patients who were C1 non-responders, 
nine were retreated with rituximab. The domains that persisted 
at grade A/B in C1 were mucocutaneous (n=4), musculo-
skeletal (n=3), renal (n=2) and haematology (n=3). After 
retreatment, none of these patients responded. Additionally, 
four patients had clinical features that were suggestive of 
immunogenicity.
retreatment of first cycle responders
Of the 96 patients who were C1 responders, 77 (with complete 
data on 72) were retreated on clinical relapse. Of these, 61/72 
(85%) responded in C2 (figure 3). Numerically higher rate of 
B-cell depletion was achieved in C2 compared with C1 (68% 
versus 58%, respectively; p=0.206) and depletion improved 
Figure 1 BILAG response and B-cell depletion following rituximab. (A) Majority of the individual domain improved post-rituximab although 
responses in the mucocutaneous and haematological domains were more varied. (B) Similar to the discovery cohort, a higher response rate was 
achieved in complete depletion compared with incomplete depletion groups; 93% versus 68%; p=0.011 in the validation cohort. (C) There was an 
incremental increase in the rates of B-cell depletion over three cycles of rituximab. ACLE, acute cutaneous lupus erythematosus; BILAG: British Isles 
Lupus Assessment Group; CCLE, chronic cutaneous lupus erythematosus; LENS, lupus erythematosus non-specific lesions.
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table 2 Multivariable analysis for predictors of major clinical response to first cycle rituximab
no response/
partial response 
n=59
Major clinical 
response n=58
univariable Or (95% CI),
p value
(with multiple imputation)
Multivariable Or (95% CI),
p value
(with multiple imputation)
Age, mean (SD) years 43 (17) 37 (14) 0.97 (0.95 to 0.99), p=0.031 per year 0.97 (0.94 to 1.00), p=0.045
White, N (%) 43 (73) 37 (64) 1.53 (0.70 to 3.34), p=0.292 0.92 (0.34 to 2.47), p=0.870
Anti-dsDNA titres, mean (SD) IU/mL 147 (230) 142 (230) 1.00 (0.99 to 1.00), p=0.879 per unit 1.00 (0.99 to 1.00), p=0.632
Anti-ENA positivity, N (%) 40 (68) 38 (66) 0.91 (0.42 to 1.99), p=0.812 0.90 (0.37 to 2.22), p=0.821
Low C3 and/or C4 titres, N (%) 25 (42) 24 (41) 0.97 (0.46 to 2.04), p=0.937 1.14 (0.41 to 3.13), p=0.801
ESR, mean (SD) mm/hour* 40 (32) 41 (36) 1.00 (0.99 to 1.01), p=0.827 per unit –
Concomitant S, N (%)† 41 (69) 35 (60) 0.67 (0.31 to 1.43), p=0.301 0.43 (0.17 to 1.09), p=0.075
Daily prednisolone dose, mean (SD) mg 13 (11) 16 (14) 1.02 (0.99 to 1.05), p=0.207 per mg 1.00 (0.97 to 1.04), p=0.713
Total BILAG score, mean (IQR) 21 (8) 24 (13) 1.03 (0.99 to 1.07), p=0.093 per point 1.02 (0.97 to 1.07), p=0.371
Total B-cell counts, mean (IQR)‡ 101 (95) 138 (150) 1.00 (1.00 to 1.01), p=0.161 per unit 1.00 (1.00 to 1.01), p=0.137
B-cell depletion at 6 weeks postrituximab, N (%) 29 (49) 39 (68) 2.10 (0.95 to 4.62), p=0.065 3.22 (1.24 to 8.33), p=0.016
*As high collinearity was observed between ESR and total B-cell counts, only the latter was included in the multivariable analysis.
†Concomitant immunosuppressant was defined as either using methotrexate, azathioprine, mycophenolate mofetil and/or other disease modifying anti-rheumatic drugs but 
excluded anti-malarials.
‡count × 109 cells/L) for each subset multiplied by 1000 prior to analysis.
BILAG, British Isles Lupus Assessment Group; C3/C4, complement 3 or 4; dsDNA, double-stranded DNA; ENA, extract nuclear antigen; ESR, erythrocyte sedimentation rate; IS, 
immunosuppressant.
Figure 2 2NDNR to rituximab and efficacy of alternative humanised anti-CD20 antibodies. (A) In this validation cohort, detection of 
plasmablasts >0.0008×109/L at 6 months predicted earlier relapse. (B) The phenomenon 2NDNR was associated with anti-rituximab antibody. The 
dotted red line represents normal cut-off of the test. (C) The Global BILAG score and CD20+ B-cells are plotted for each patient. The black line in 
the CD20+ B-cells figure represents the median. (D) An example of a case where proteinuria was normalised following a switch to ocrelizumab. ‘RR’ 
represents 2x infusions of rituximab, ‘R’ represents a single infusion as the patient cannot not complete the second due to severe infusion reaction 
and ‘OO’ represents 2x infusions of ocrelizumab. The total B-cell counts were transformed to natural log. 2NDNR, secondary non-depletion non-
response; BILAG, British Isles Lupus Assessment Group.
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over subsequent cycle, C3 versus C1 (79% vs 58% respec-
tively; p=0.022) (figure 1C).
Twelve out of 38 patients who were C1 partial responders 
were retreated at 6 months. Of these, major clinical response 
was achieved in 10/12 (83%) in C2. One patient had worsening 
of arthritis, while another had 2NDNR in C2.
Of the 11 patients who were C2 non-responders, nine met 
2NDNR criteria. Therefore, the incidence of 2NDNR in this 
cohort was 9/77 (12%). In C3, another two patients had 2NDNR.
Association of 2ndnr with antirituximab antibody
Post-rituximab sera for 5/9 patients with 2NDNR were tested 
for anti-rituximab antibodies. Of these, all 5/5 (100%) were 
tested positive. In contrast, of the 16 patients who were 
C2 responders, 9/16 (56%) were also tested positive for 
anti-rituximab antibodies. The median anti-rituximab levels 
were higher in the former, 562 (IQR 394–9670) AU/mL 
compared with the latter, 217 (IQR 0–409) AU/mL; p=0.024 
(figure 2B).
Factors associated with 2ndnr
Risk factors for 2NDNR were lack of concomitant immuno-
suppressant (p=0.023) and higher pre-rituximab plasmablasts 
(p<0.001) (table 3). Concomitant corticosteroid dose, duration 
of response in C1, clinical response category in C1, pre-ritux-
imab global BILAG score, pre-rituximab naïve and memory 
B-cells were not associated with 2NDNR; all p>0.10.
efficacy of switching to humanised anti-Cd20 antibodies
Following 2NDNR, treatment for five patients were switched 
to humanised anti-CD20 mAbs (3=ocrelizumab and 2=ofatu-
mumab). Post-treatment, complete depletion of CD20+ cells 
were achieved in 4/5 patients, while the remaining one had 
substantially low counts (0.0016×109/L).
The median global BILAG scores had reduced from 24 (IQR 
18–45) pre-treatment to 1 (IQR 0–8) post-treatment; p=0.008 
(figure 2C). The individual BILAG response is shown in figure 2D 
and described in online supplementary table S5. One patient with 
Figure 3 Efficacy of repeat cycles with rituximab in systemic lupus erythematosus. There was a high rate of initial clinical response to rituximab in 
this cohort, 96/117 (82%). Seventy-seven responders who had clinical relapse were retreated in C2. Of these, 61/72 (85%) continued to response in 
C2. Of the C2 non-responders, 9/11 met 2NDNR criteria. Five were switched to ocrelizumab/ofatumumab resulted in depletion and response in all. 
2NDNR, secondary non-depletion and non-response; C1, cycle 1.
table 3 Factors associated with secondary non-depletion non-response to rituximab (2NDNR)
Characteristics prior to rituximab retreatment Continued to respond (n=61) 2ndnr (n=9) p Value
Concomitant IS, N (%) 41 (67) 2 (22) 0.023
Prednisolone, median (IQR) mg 5 (0–10) 5 (0–17.5) 0.729
Duration of response, median (IQR) weeks 50 (36–107) 62 (52–164) 0.239
Total BILAG score, median (IQR) 16 (12–21) 24 (12–27) 0.209
Partial clinical response in cycle 1, N (%) 24 (39) 3 (33) 0.731
Naïve B-cells, median (IQR) 109 cells/L 0.0349 (0.0071–0.0735) 0.0620 (0.0101–0.0950) 0.296
Memory B-cells, median (IQR) x 109/L 0.0019 (0.0010–0.0047) 0.0090 (0.0054–0.0394) 0.175
Plasmablasts, median (IQR) x 109/L 0.0011 (0.0004–0.0036) 0.0086 (0.0052–0.0227) <0.001
*NDNR, secondary non-depletion and non-response; IS, immunosuppressant.
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class IV-G (active with moderate scarring) who had progressed into 
end-stage renal failure was treated with ofatumumab, mainly for 
severe thrombocytopaenia with a view for renal transplantation 
preparation. Post-treatment, her platelet had normalised from 
45×109/L (pre-treatment), renal parameters were stable and she 
successfully underwent live donor renal transplantation.
dIsCussIOn
The clinical challenges for the use of rituximab in SLE include 
defining subgroups of patients likely to respond to the initial 
and subsequent cycles and optimal repeat treatment strategy. 
By capturing data of all patients with SLE who were treated 
with rituximab in this largest reported cohort, as well as long-
term follow-up, this study offers insights into pragmatic use of 
rituximab and has implications for the future development of 
targeted therapies.
In this study, the only consistent predictor of any (and major) 
clinical response to rituximab is B-cell depletion (as measured 
using HSFC) at 6 weeks post-rituximab, which we have now 
validated in an independent cohort. This underlines the immu-
nomodulatory action of rituximab in correcting autoimmune 
B-cell function and normalising autoantibody titres and comple-
ment levels without increasing the risk of severe infection. 
From treatment stratification perspective, our data support the 
rationale for B-cell monitoring during therapy. Thus, prior to 
rituximab, by assessing patients for low complement levels and 
higher plasmablasts, treatment modification can be employed 
to improve depletion, either by increasing the dose or adding 
an extra infusion, as we previously showed in RA.21 At 6 weeks 
post-rituximab, complete depletion is a marker of good response 
to therapy. For those with incomplete depletion, close moni-
toring is required. At 6 months post-rituximab, repopulation 
of plasmablasts of >0.0008×109/L increases the risk of clinical 
relapse within the following 6 months. Therefore, these patients 
can be considered for early retreatment in order to reduce the 
higher burden of B-cell numbers and enhance depletion in 
the subsequent cycle. Importantly, for those with plasmablasts 
of ≤0.0008×109/L at 6 months, monitoring for clinical relapse 
would appear an acceptable strategy.
Regardless of response, about 12% subsequently developed 
2NDNR in C2. This phenomenon is associated with rituximab 
anti-drug antibodies. However, measuring anti-rituximab anti-
body alone is not enough to identify patients as 2NDNR as over 
half of the patients who were tested positive responded in that 
particular cycle. Instead, clinical features, that is, severe infu-
sion reaction and non-response and measuring B-cells, are more 
meaningful. Lack of concomitant oral immunosuppressant and 
higher pre-rituximab plasmablasts predicted 2NDNR. Oral 
immunosuppressant use was decided at physician discretion, but 
our data suggest they might have a role in preventing immunoge-
nicity. The exact mechanism for the association with plasmablast 
number is unknown, but plasmablasts are markers for overall 
B-cell activation. Following initial depletion with rituximab, 
B-cell-activating factor levels increase and promote the formation 
of plasmablasts.22 This early increase in plasmablasts enhances 
the formation of follicular T-helper cells, thus creating a positive 
feedback loop that perpetuates antibody-driven inflammation 
and may explain why some patients become refractory to ritux-
imab in SLE.23
Following 2NDNR to rituximab, switching to humanised 
anti-CD20 mAbs restores depletion and response in SLE. Ocrel-
izumab and ofatumumab are both type 1 anti-CD20 mAbs. The 
primary endpoint was met in ocrelizumab-treated groups in RA 
trials24 and was investigated in SLE.25 However, development 
in these indications was halted after an increase in opportu-
nistic infections, some of which fatal were reported.26 All three 
patients in our study had major clinical responses and prolonged 
remission for over 5-year period post-ocrelizumab. Ofatumumab 
is licenced for resistant chronic lymphocytic leukaemia and 
has demonstrated efficacy in RA.27 Both patients in our study 
responded well to ofatumumab included one who achieved 
complete depletion for the first time from B-cell depleting 
therapy. Additionally, a few case series have recently reported on 
its efficacy in extrarenal and refractory lupus nephritis.28 29 Alter-
natively, other anti-CD20 agents with enhanced antibody-depen-
dent cellular cytotoxicity may be more effective in SLE. In vitro 
obinutuzumab demonstrated enhanced depletion was achieved 
with this type 2 mAb, compared with rituximab.30
This study has several limitations. First, an interobserver vari-
ability could have occurred in BILAG assessments due to the 
lengthy follow-up duration and a cohort that was highly hetero-
geneous in lupus manifestations. However, the BILAG scores 
reflected the clinician’s intention-to-treat, and the patients 
were managed in a dedicated single centre, thus allowing for 
consistency in assessment. Second, B-cells and laboratory data 
were missing in some cases. As these were deemed missing at 
random, multiple imputation was used to reduce potential bias 
in parameter estimation as well as enhancing generalisability of 
the results. Next, concomitant therapy with immunosuppressant 
were used in more than 60% of the patients, thus efficacy could 
not be attributed to rituximab alone. Lastly, the lack of control 
group limits interpretation of efficacy and safety of rituximab.
In conclusion, treatment with anti-CD20 agents can be 
guided by B-cell monitoring with the aim of achieving complete 
depletion. About one in eight patients with SLE lose deple-
tion on repeat cycles of rituximab regardless of prior response 
and secondary non-depletion is associated with anti-rituximab 
antibodies. Concomitant oral immunosuppressant may help to 
prevent this. If 2NDNR occurs, switching to humanised anti-
CD20 mAbs restores depletion and response. Therefore, alter-
native anti-CD20 antibodies may be more consistently effective 
in SLE treatment and several ongoing trials are addressing these 
issues.
Correction notice this article has been corrected since it published online First. 
the abstract has been corrected.
Acknowledgements the authors would like to thank Elizabeth M Hensor for 
statistical advice, clinicians, pharmacist, study coordinator and lab technicians at 
the Leeds Connective tissue disease and Vasculitis Clinic particularly Mike Martin, 
Jacqueline Andrews, Maya Buch, Colin pease, Shouvik dass, Sinisa Savic, John 
Bamford, paul Beirne, Mark Goodfield, tina Hawkins, Huma Cassamoali, diane 
Corscadden and Katie Mbara for their substantial contribution in the acquisition of 
the data.
Contributors MYMY, pE and EMV: substantial contributions to the conception or 
design of the work, or the acquisition, analysis or interpretation of data, drafting the 
work or revising it critically for important intellectual content, final approval of the 
version published and agreement to be accountable for all aspects of the work in 
ensuring that questions related to the accuracy or integrity of any part of the work 
are appropriately investigated and resolved. dS, YME-S, Ed and ACr: substantial 
contributions to the conception or design of the work, or the acquisition, analysis 
or interpretation of data, drafting the work or revising it critically for important 
intellectual content and final approval of the version published.
Funding this research was funded/supported by the national Institute for Health 
research (nIHr) and nIHr Leeds Biomedical research Centre based at Leeds 
teaching Hospitals nHS trust; and nIHr research Grants (drF-2014-07-155) 
and (CS-2013-13-032). the views expressed are those of the author(s) and not 
necessarily those of the nHS, the nIHr or the department of Health.
Competing interests EMV is an nIHr Clinician Scientist. He has received 
honoraria and research grant support from roche, GSK and AstraZeneca. pE has 
received consultant fees from BMS, Abbott, pfizer, MSd, novartis, roche and UCB. He 
 o
n
 15 M
ay 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2017-211191 on 6 July 2017. Downloaded from
 
1836 Md Yusof MY, et al. Ann Rheum Dis 2017;76:1829–1836. doi:10.1136/annrheumdis-2017-211191
Clinical and epidemiological research
has received research grants paid to his employer from AstraZeneca, Abbott, BMS, 
pfizer, MSd and roche.
Patient consent the study does not contain any personal medical information 
about an identifiable living individual, thus patient consent is not required.
ethics approval the use of rituximab, ofatumumab and ocrelizumab were all 
approved by Leeds teaching Hospitals nHS trust drug and therapeutic Committee. 
Analysis of samples for antirituximabantibody was approved by the Leeds (East) 
research Ethics Committee (rEC), 10/H1306/88, and the committee confirmed that 
other aspects of the study did not require ethical approval in accordance with the UK 
national Health Service rEC guidelines.
Provenance and peer review not commissioned; externally peer reviewed.
Open Access this is an open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others 
to distribute, remix, adapt and build upon this work, for commercial use, provided 
the original work is properly cited. See: http:// creativecommons. org/ licenses/ by/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. no commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1 Aguiar r, Araújo C, Martins-Coelho G, et al. Use of rituximab in systemic lupus 
erythematosus: a single Center experience over 14 years. Arthritis Care Res 
2017;69:257-262.
 2 Vital EM, dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic 
lupus erythematosus. Arthritis Rheum 2011;63:3038–47.
 3 Galarza-Maldonado C, Kourilovitch Mr, Molineros JE, et al. the administration of 
low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of 
mycophenolate mofetil is an effective therapy in latin american patients with active 
systemic lupus erythematosus. Autoimmun Rev 2010;10:108–11.
 4 díaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with 
biopsy-proven lupus nephritis: pooled data from european cohorts. Autoimmun Rev 
2012;11:357–64.
 5 Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab 
in refractory lupus: data from the italian Multicentre registry. Clin Exp Rheumatol 
2015;33:449–56.
 6 Witt M, Grunke M, proft F, et al. Clinical outcomes and safety of rituximab treatment 
for patients with systemic lupus erythematosus (SLE) - results from a nationwide 
cohort in Germany (GrAId). Lupus 2013;22:1142–9.
 7 ramos-Casals M, Soto MJ, Cuadrado MJ, et al. rituximab in systemic lupus 
erythematosus: a systematic review of off-label use in 188 cases. Lupus 
2009;18:767–76.
 8 Merrill Jt, neuwelt CM, Wallace dJ, et al. Efficacy and safety of rituximab in 
moderately-to-severely active systemic lupus erythematosus: the randomized, double-
blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis 
Rheum 2010;62:222–33.
 9 rovin BH, Furie r, Latinis K, et al. Efficacy and safety of rituximab in patients with 
active proliferative lupus nephritis: the Lupus nephritis Assessment with rituximab 
study. Arthritis Rheum 2012;64:1215–26.
 10 Md Yusof MY, Vital EM, Emery p. B-cell-targeted therapies in systemic lupus 
erythematosus and AnCA-associated vasculitis: current progress. Expert Rev Clin 
Immunol 2013;9:761–72.
 11 reddy V, Croca S, Gerona d, et al. Serum rituximab levels and efficiency of B cell 
depletion: differences between patients with rheumatoid arthritis and systemic lupus 
erythematosus. Rheumatology 2013;52:951–2.
 12 reddy V, Cambridge G, Isenberg dA, et al. Internalization of rituximab and the 
efficiency of B cell depletion in rheumatoid arthritis and systemic lupus erythematosus. 
Arthritis Rheumatol 2015;67:2046–55.
 13 Alexander t, Sarfert r, Klotsche J, et al. the proteasome inhibitior bortezomib depletes 
plasma cells and ameliorates clinical manifestations of refractory systemic lupus 
erythematosus. Ann Rheum Dis 2015;74:1474–8.
 14 Liu Z, Zou Y, davidson A. plasma cells in systemic lupus erythematosus: the long and 
short of it all. Eur J Immunol 2011;41:588–91.
 15 dass S, rawstron AC, Vital EM, et al. Highly sensitive B cell analysis predicts 
response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 
2008;58:2993–9.
 16 Hochberg MC. Updating the American College of rheumatology revised criteria for 
the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
 17 Isenberg dA, rahman A, Allen E, et al. BILAG 2004. development and initial 
validation of an updated version of the british Isles Lupus Assessment Group’s 
disease activity index for patients with systemic lupus erythematosus. Rheumatology 
2005;44:902–6.
 18 Yee CS, Cresswell L, Farewell V, et al. numerical scoring for the BILAG-2004 index. 
Rheumatology 2010;49:1665–9.
 19 Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B 
cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis 
Rheumatol 2015;67:1586–91.
 20 Vital EM, dass S, rawstron AC, et al. Management of nonresponse to rituximab 
in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 
2010;62:1273–9.
 21 Vital EM, dass S, Buch MH, et al. An extra dose of rituximab improves clinical 
response in rheumatoid arthritis patients with initial incomplete B cell depletion: a 
randomised controlled trial. Ann Rheum Dis 2015;74:1195–201.
 22 Carter LM, Isenberg dA, Ehrenstein Mr. Elevated serum BAFF levels are associated 
with rising anti-double-stranded dnA antibody levels and disease flare following 
B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 
2013;65:2672–9.
 23 Ehrenstein Mr, Wing C. the BAFFling effects of rituximab in lupus: danger ahead? Nat 
Rev Rheumatol 2016;12:367–72.
 24 rigby W, tony Hp, oelke K, et al. Safety and efficacy of ocrelizumab in patients with 
rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-
eight-week randomized, double-blind, placebo-controlled, parallel-group phase III 
trial. Arthritis Rheum 2012;64:350–9.
 25 Mysler EF, Spindler AJ, Guzman r, et al. Efficacy and safety of ocrelizumab in active 
proliferative lupus nephritis: results from a randomized, double-blind, phase III study. 
Arthritis Rheum 2013;65:2368–79.
 26 Emery p, rigby W, tak pp, et al. Safety with ocrelizumab in rheumatoid arthritis: results 
from the ocrelizumab phase III program. PLoS One 2014;9:e87379.
 27 Østergaard M, Baslund B, rigby W, et al. ofatumumab, a human anti-Cd20 
monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate 
response to one or more disease-modifying antirheumatic drugs: results of a 
randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 
2010;62:2227–38.
 28 thornton CC, Ambrose n, Ioannou Y. ofatumumab: a novel treatment for severe 
systemic lupus erythematosus. Rheumatology 2015;54:559–60.
 29 Haarhaus ML, Svenungsson E, Gunnarsson I. ofatumumab treatment in lupus 
nephritis patients. Clin Kidney J 2016;9:552–5.
 30 reddy V, Klein C, Isenberg dA, et al. obinutuzumab outperforms rituximab at 
inducing b-cell cytotoxicity in vitro through fc-mediated effector mechanisms in 
rheumatoid arthritis and systemic lupus erythematosus. Arthritis & Rheumatology 
2015;67:1442–5.
 o
n
 15 M
ay 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2017-211191 on 6 July 2017. Downloaded from
 
